ROP babies should be screened at 12 months

Article

It is recommended that all babies with retinopathy of prematurity (ROP) be screened at 12 months to identify amblyogenic factors such as squint and refractive error.

It is recommended that all babies with retinopathy of prematurity (ROP) be screened at 12 months to identify amblyogenic factors such as squint and refractive error, according to a report published in the January/February issue of the European Journal of Ophthalmology.

Elizabeth Cosgrave and colleagues from Ipswich Hospital, Suffolk, UK retrospectively reviewed the case notes of 211 babies for birth details, maternal details, presence of ROP, and for the findings of follow-up screenings.

At one-year follow-up, 16.6% of ROP positive children failed a screening visit because of squint (6.66%), refractive error (6.66%) and optic nerve abnormalities (3.33%).

It is therefore advised that babies with ROP be screened at 12 months in order to identify amblyogenic factors.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.